跳到正文
原文
Medical Xpress·· 2026-10-03AI 评分36

代谢物衍生三肽化合物 MLY2 与 MLY8 在小鼠实验性结肠炎及人难治性溃疡性结肠炎组织中显示抗炎活性

Metabolite-inspired compounds show promise for ulcerative colitis drug discovery

AI 导读

乔治亚州立大学团队在 International Journal of Molecular Sciences 报告,基于抗炎代谢物 M13 结构优化的化合物 MLY2 和 MLY8 在小鼠实验性结肠炎中改善多项疾病活动指标,包括恢复结肠长度、降低粪便 lipocalin-2。

正文
Metabolite-inspired compounds show promise for ulcerative colitis drug discovery, study finds
Phase II metabolite-inspired tripeptide editing identifies NF-κB inhibitory analogs. Credit: International Journal of Molecular Sciences (2026). DOI: 10.3390/ijms27188285

Two structurally modified compounds derived from an anti-inflammatory metabolite demonstrated enhanced anti-inflammatory activity in experimental ulcerative colitis in mice and human tissue, offering an underexplored drug discovery opportunity for this chronic inflammatory disease, according to a study led by researchers in the Institute for Biomedical Sciences at Georgia State University.

The findings, published in the International Journal of Molecular Sciences, suggest that two selected compounds, MLY2 and MLY8, improved multiple measures of disease activity in experimental colitis in mice, including restoration of colon length and reduction of fecal lipocalin-2 (a biomarker of intestinal inflammation).

In laboratory-cultured colon tissue samples from patients with treatment-refractory ulcerative colitis, both compounds suppressed inflammatory cytokine production more effectively than M13, the study's lead metabolite, supporting further preclinical investigations of MLY2 and MLY8.

Ulcerative colitis, a chronic inflammatory disease of the gastrointestinal tract, remains a major clinical challenge because of the limited availability of safe, orally active anti-inflammatory drugs. Despite major advances in therapies, a considerable proportion of patients fail to achieve sustained remission or experience loss of response over time, highlighting the need for safer and more effective anti-inflammatory drug candidates.

Phase II metabolism is traditionally viewed as a detoxification and deactivation process, but emerging evidence suggests that certain metabolites retain or exhibit enhanced pharmacological activity, offering an underexplored drug discovery opportunity.

M13 was previously identified as a biologically active metabolite (a compound produced during metabolism) with enhanced anti-inflammatory activity and improved biopharmaceutical properties compared with its parent compound, 6-shogaol, suggesting that metabolites can provide valuable starting points for identifying new biologically active compounds.

In this study, the researchers investigated whether phase II metabolites could serve as chemically productive scaffolds for drug discovery and whether selective editing of the glutathione tripeptide sequence could improve anti-inflammatory activity and generate anti-inflammatory leads with improved biological activity.

Using M13 as the lead structure for medicinal chemistry optimization, the researchers evaluated MLY2 and MLY8 in dextran sulfate sodium–induced experimental colitis in mice, laboratory-cultured colon tissue samples from patients with treatment-refractory ulcerative colitis and preliminary safety and tolerability studies.

"This work shows that modifying the chemical structure of a biologically active phase II metabolite can be a productive strategy for discovering new anti-inflammatory drug candidates," said Chunhua Yang, senior author of the study and a research assistant professor in the Institute for Biomedical Sciences at Georgia State. "The findings provide a foundation for follow-up studies, suggesting that biologically active phase II metabolites may represent underutilized scaffolds for medicinal chemistry optimization in inflammatory disease."

Publication details

Xiaodi Shi et al, Phase II Metabolite-Inspired Tripeptide Editing Generates Anti-Inflammatory Candidates for Treatment-Refractory Ulcerative Colitis, International Journal of Molecular Sciences (2026). DOI: 10.3390/ijms27188285

Journal information: International Journal of Molecular Sciences

Key medical concepts

Ulcerative Colitis

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Metabolite-inspired compounds show promise for ulcerative colitis drug discovery (2026, October 2) retrieved 2 October 2026 from https://medicalxpress.com/news/2026-10-metabolite-compounds-ulcerative-colitis-drug.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com